Pharmacological or siRNA mediated inhibition of GSK-3β has been shown to reduce NF-κB mediated gene transcription and inhibit the growth of cancers that show high NF-κB activity including pancreatic cancer [8,27,28]. The gene discussed is NFKB1; the disease is cancer.